Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVBFJP)

Drug Name

MK-0668 Drug Info

Synonyms

MK-0668; UNII-S441P37178; CHEMBL506044; S441P37178; 865110-07-2; SCHEMBL13884454; BDBM50423686; N-(N-((3-Cyanophenyl)sulfonyl)-4(R)-cyclobutylamino-(l)-prolyl)-4-((3',5'-dichloroisonicotinoyl) amino)-(l)-phenylalanine; L-Phenylalanine, (4R)-1-((3-cyanophenyl)sulfonyl)-4-(cyclobutylamino)-L-prolyl-4-(((3,5-dichloro-4-pyridinyl)carbonyl)amino)-

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11433918
CAS Number: CAS 865110-07-2
TTD Drug ID: DMVBFJP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Integrin beta-1 (ITGB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
131I-radretumab	DMT17XU	Non-small-cell lung cancer	2C25.Y	Phase 1/2	[2]
JSM 6427	DM4QIOH	Macular degeneration	9B78.3	Phase 1	[3]
OS2966	DMS8NM5	Glioblastoma of brain	2A00.00	Phase 1	[4]
C(-GRGDfL-)	DMTMJAI	Discovery agent	N.A.	Investigative	[5]
SB-265123	DM8UKH7	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------

Drug(s) Targeting ITGA4 messenger RNA (ITGA4 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ATL1102	DM3POT6	Multiple sclerosis	8A40	Phase 2	[7]
ISIS 24477	DMCNBIL	Discovery agent	N.A.	Investigative	[8]
ISIS 24448	DMLHQ2J	Discovery agent	N.A.	Investigative	[8]
ISIS 24453	DM45WUZ	Discovery agent	N.A.	Investigative	[8]
ISIS 24475	DMBKZOQ	Discovery agent	N.A.	Investigative	[8]
ISIS 24454	DMDE3J1	Discovery agent	N.A.	Investigative	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Integrin beta-1 (ITGB1)	TTBVIQC	ITB1_HUMAN	Inhibitor	[1]
ITGA4 messenger RNA (ITGA4 mRNA)	TTJMF9P	ITA4_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Discovery of N-{N-[(3-cyanobenzene) sulfonyl]-4(R)-(3,3-difluoropiperidin-1-yl)-(l)-prolyl}-4-[(3',5'-dichloro-isonicotinoyl) amino]-(l)-phenylalan... Bioorg Med Chem Lett. 2009 Oct 1;19(19):5803-6.
2	Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study. Cancer Immunol Res. 2013 Aug;1(2):134-43.
3	An alpha5beta1 integrin inhibitor attenuates glioma growth. Mol Cell Neurosci. 2008 Dec;39(4):579-85.
4	Convection-Enhanced Delivery of a First-in-Class Anti-beta1 Integrin Antibody for the Treatment of High-Grade Glioma Utilizing Real-Time Imaging. Pharmaceutics. 2020 Dec 30;13(1):40.
5	Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem. 2007 Nov 29;50(24):5878-81.
6	Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model. Bioorg Med Chem Lett. 1999 Jul 5;9(13):1807-12.
7	CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS.Neurology.2014 Nov 11;83(20):1780-8.
8	US patent application no. 6,258,790, Antisense modulation of integrin .alpha.4 expression.